Literature DB >> 26436750

Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness.

Purav Mody1, Oanh Kieu Nguyen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26436750      PMCID： PMC5330662          DOI： 10.1001/jamainternmed.2015.4000

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  1 in total

1.  Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.

Authors:  Jean S Kutner; Patrick J Blatchford; Donald H Taylor; Christine S Ritchie; Janet H Bull; Diane L Fairclough; Laura C Hanson; Thomas W LeBlanc; Greg P Samsa; Steven Wolf; Noreen M Aziz; David C Currow; Betty Ferrell; Nina Wagner-Johnston; S Yousuf Zafar; James F Cleary; Sandesh Dev; Patricia S Goode; Arif H Kamal; Cordt Kassner; Elizabeth A Kvale; Janelle G McCallum; Adeboye B Ogunseitan; Steven Z Pantilat; Russell K Portenoy; Maryjo Prince-Paul; Jeff A Sloan; Keith M Swetz; Charles F Von Gunten; Amy P Abernethy
Journal:  JAMA Intern Med       Date:  2015-05       Impact factor: 21.873
  1 in total
  2 in total

1.  Drug prescribing during the last year of life in very old people with diabetes.

Authors:  Shota Hamada; Martin C Gulliford
Journal:  Age Ageing       Date:  2017-01-15       Impact factor: 10.668

2.  Discussion around statin discontinuation in older adults and patients with wasting diseases.

Authors:  Maciej Banach; Maria-Corina Serban
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-29       Impact factor: 12.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.